CD274 and esophageal squamous cell carcinoma: In conclusion, our study suggested that FR4 can be used as a marker of postoperative adjuvant chemotherapy benefit in esophageal squamous cell carcinoma, and FR4 is a marker of Treg and TAM, which has a certain correlation with PD-L1 expression.